Jeffrey Jones, MD, MPH, on Chronic Lymphocytic Leukemia: Optimizing Treatment With New Agents
2016 NCCN Annual Conference (1)
Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
William Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University, discusses updates including preoperative HER2-directed therapy, optimal adjuvant endocrine treatment in premenopausal women, and an approach for managing ER+ metastatic disease.
Douglas E. Wood, MD, of the University of Washington, discusses best practices, which enable a complete workup in 1 to 2 weeks in almost all patients, saving unnecessary testing.
Nadeem Abu-Rustum, MD, of Memorial Sloan Kettering Cancer Center, discusses improvements in fertility-sparing surgery for young women, advances in lymph node assessment, and the evolving role of chemotherapy and radiation.
Daniel T. Chang, MD, of the Stanford Cancer Institute, discusses the role of radiation therapy in the treatment of hepatocellular carcinoma.